Archive for July, 2020

Hansa grants Sarepta exclusive license to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy, for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV).

Under the terms of the license: Hansa will receive a USD 10 million upfront payment and is eligible for up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase and would be eligible for royalties in the high single-digits to mid-teens on any gene therapy sales enabled through pre-treatment with imlifidase in NAb-positive patients.

Lund, Sweden July 2, 2020. Hansa Biopharma (Hansa), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced today that it has entered into an agreement with Sarepta Therapeutics Inc. (Sarepta), the leader in precision genetic medicine for rare diseases, through which Sarepta is granted an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD). The pre-treatment is intended for patients with pre-existing neutralizing antibodies (NAb-positive patients) to adeno-associated virus (AAV), the technology that is the basis for Sareptas gene therapy products.

Sarepta will be responsible for conducting pre-clinical and clinical studies with imlifidase and any subsequent regulatory approvals. Sarepta will also be responsible for the promotion of imlifidase as a pre-treatment to Sareptas gene therapies following potential approval.

Under the terms of the agreement, Hansa will receive a USD 10 million upfront payment, and is eligible for a total of up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase, and earn high single-digit to mid-teens royalties on Sareptas incremental gene therapy sales when treating NAb-positive patients enabled through pre-treatment with imlifidase.

Sren Tulstrup, President & CEO of Hansa Biopharma comments,We see significant potential for our enzyme technology in the gene therapy space overall, and we are excited to partner with Sarepta, a leading player in the field, to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today arent eligible for these breakthrough therapies due to pre-existing neutralizing antibodies in two conditionswith a very high unmet medical need.

Doug Ingram, President & CEO, Sarepta Therapeutics said,As we expand our leadership position in genetic medicine and build out our gene therapy engine, one of Sareptas central ambitions is to find scientific solutions that bring our potentially life-saving therapies to the greatest number of the rare disease patients we serve. One of the current limitations of gene therapy is the inability to treat patients who have pre-existing neutralizing antibodies to the AAV vector. While our AAVrh74 vector has been associated with a low screen out rate for neutralizing antibodies, even that low rate is inconsistent with our mission.

In pre-clinical and clinical models, Hansas technology has shown the ability to clear the IgG antibodies that prevent dosing AAV-based gene therapies. If successful, this could offer the potential of extending our gene therapy treatments to DMD and LGMD patients who would otherwise have been denied access due to pre-existing antibodies.

Hansa Biopharma will be hosting a conference call with President & CEO Sren Tulstrup, CSO & COO Christian Kjellman and CFO Donato Spota.

Conference Call Partnership agreement with Sarepta TherapeuticsA conference call will take place July 2nd, 2020 at 10:00am CET. The audio cast will be recorded and subsequently be available on the Hansa website https://hansa.eventcdn.net/202007

Participants dial-in numbersSE: + 46 81 241 09 52UK: + 44 203 769 6819US: + 1 646 787 0157

This is information that HansaBiopharma AB is obliged to makepublic pursuant to the EU MarketAbuse Regulation.

About imlifidaseImlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response. It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020.Hansa has also reached an agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S. and has three ongoing phase 2 trials in autoimmune diseases and post-transplant indications.

About gene therapy and neutralizing antibodiesGene therapy is a growing and revolutionizing treatment technology in which healthy gene sequences are inserted into cells of a patient. The treatments are potentially curative in monogenic diseases like hemophilia and muscular dystrophy through a single dose. Harmless recombinant viruses are used to carry the healthy genes into the cell. Due to the partial viral origin of the gene therapy constructs, a certain subset of patients carry neutralizing anti-AAV antibodies towards gene therapy products, depending on what AAV serotype being used, forming a barrier for treatment eligibility.Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern. Imlifidase as a pre-treatment may have the potential to eliminate neutralizing antibodies prior to gene therapy. Similarly, imlifidase may have the potential to enable any potentially necessary re-dosing of gene therapy for all patients.

About Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy is a rare genetic disease caused by mutation in the DMD gene, encoding for the protein dystrophin. Duchenne is an irreversible, progressive disease that causes the muscles in the body to become weak and damaged over time. It is eventually fatal and there is no cure. DMD affects one in 3,500 to 5,000 males born worldwide (approximately 400-500 annual cases in the US) and causes muscles in the body to become weak and most patients use wheelchair by the age of 12.

About Limb-Girdle Muscular Dystrophy (LGMD)Limb-girdle muscular dystrophy or (LGMD) is a genetically and clinically heterogeneous group of rare muscular dystrophies. It is characterised by progressive muscle wasting which affects predominantly hip and shoulder muscles. LGMD has an autosomal pattern of inheritance and currently has no known cure or treatment. It can be caused by a single gene defect that affects specific proteins within the muscle cell, including those responsible for keeping the muscle membrane intact. LGMD has a global prevalence of approximately 1.63 per 100,000 individuals worldwide.

For further information, please contact:Klaus Sindahl, Head of Investor RelationsHansa Biopharma Mobile: +46 (0) 709-298 269E-mail: klaus.sindahl@hansabiopharma.com

About Hansa BiopharmaHansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.The Companys lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansas research and development program is advancing the next generation of the Companys technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

View original post here:
Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se...

The report covers the forecast and analysis of the Cell and Gene Therapy Consumables market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the Cell and Gene Therapy Consumables market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell and Gene Therapy Consumables market on a global level.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10172657

In order to give the users of this report a comprehensive view of the Cell and Gene Therapy Consumables market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service & product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the Cell and Gene Therapy Consumables market by segmenting the market based on product type, application/therapeutics, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

A rise in the awareness about the gene & cell therapies will propel the market growth during the period from 2019 to 2027. Nevertheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

The expansion of the market during the forecast timespan is owing to the high frequency of chronic ailments including cancer and heart disorders. Apart from this, inflation in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast time span.

Request For Full Report:https://www.kennethresearch.com/sample-request-10172657

Based on the product type, the market is sectored into Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media. Application/ Therapeutics- wise, the market for cell and gene therapy consumables are classified into Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Original post:
Cell And Gene Therapy Consumables Market Size, Share And Top Key Players During 2020-2027 Bulletin Line - Bulletin Line

No matter how many molecules he threw at them, Paul Tesar couldnt get the brain cells to survive. Or he got them to survive, but then to everyones bafflement they still couldnt do what they were supposed to.

Tesar, a professor of innovative therapeutics at Case Western University, had spent years building stem cell models for multiple sclerosis, growing brain organoids in dishes and then seeing what small molecules restored myelin production. Now he was trying to do the same for other myelin diseases, particularly an ultra-rare genetic condition called Pelizaeus-Merzbacher disease, where a single mutation leads to the death of the myelin-producing neurons, called oligodendrocytes, and can kill patients in infancy.

Weve screened many thousands of small molecule compounds, Tesar toldEndpoints News. But we could not get them to restore function.

Then Tesar got an email from Ionis, the California biotech that had just used an RNA-modifying technology called antisense to build Spinraza, the first FDA-approved drug for the genetic neurological disorder spinal muscular atrophy.

Now, in a study published inNature,Tesar and Ionis have shown they can use a single dose of drug built from that technology to keep those neurons both alive and well-functioning and treat the disease at least in mice. The publication isnt groundbreaking, antisense researchers say, but it shows for the first time that antisense can be used to effectively target oligodendrocytes, an insight its authors hope will open up other rare myelin disorders to therapy.

Its not that its different than everything thats been done before, but it goes further than everything thats gone before, Jon Watts, a professor at the RNA Therapeutics Institute at UMass Medical School who is not affiliated with Ionis or the paper, told Endpoints, both in terms of duration of effect after a single dose, and the real focus in getting the biology, the therapeutic effect in oligodendrocytes.

The applicability to the most famous and common of myelin disorders, multiple sclerosis, is limited, researchers say, both because the therapy relied on having a specific gene to target and because the paper doesnt prove you can get an effect on the peripheral nervous system. Still, Berit Powers, an assistant director at Ioniss neurology research department and a co-author, pointed to several other genetic myelin disorders, known as leukodystrophies. That includes an Ionis program on Alexander disease, a rare childhood condition with Parkinsons-like symptoms.

Were certainly exploring the potential of ASOs in non-monogenic conditions like MS, Powers told Endpoints, using a shorthand for antisense oligonucleotides. But that work is very new.

This is hardly Tesars first foray into biotech. In 2015, he showed in Naturehow certain small molecules could regenerate myelin the holy grail for an MS therapy and founded Convelo Therapeutics around that work. Last year, they partnered with Genentech for an undisclosed sum and an exclusive option to acquire the company.

Myelin is a fatty substance that coats neurons, insulating them and helping electric currents pass through. Tesars lab was broadly interested in the question of why myelin fails, both in MS and rare diseases, and about 7 years ago he got a grant to work from the PMD Foundation.

First, Tesar built stem cell models of the disease, figuring out how different mutations in a single gene, called PLP1, lead oligodendrocyte progenitor cells (the stem cell-like cells that will become oligodendrocytes) to create a toxic RNA and a mutated protein that kills them soon after they differentiate. Then, he tried to suppress that gene with different chemicals, eventually testing over 3,000 different compounds.

He was able to eventually get the oligodendrocytes to survive, but to his surprise, they didnt produce myelin as they should. The surviving cells still couldnt properly function, revealing, he wrote in a 2018 Cell paper a second phase of pathology. A hypothetical treatment, he argued, would have to both keep progenitor cells alive and then treat the survivors in a way that induces myelination.

With antisense, he and Powers Ionis team were able to do both. Antisense oligonucelotides consist of strands of RNA that are a mirror image of the RNA you want to target. The mirror binds to and silences, or turns off, that gene. In the study, the researchers confirmed that PLP1 was disease-causing by knocking out the gene in cell lines with CRISPR. Then they injected mice with antisense strands through the spinal cord, the same way Spinraza is delivered. (You cant use CRISPR to treat the disease in humans, because theres no good way yet of delivering it.)

Powers and Tesar were unsure if they would be able to target oligodendrocytes and progenitor cells. What they found, though, was complete restoration of oligodendrocytes and a profound rescue of neurological function. Myelin, too, was finally restored. Mice that died after 3 weeks now lived for over 200 days.

Ionis hasnt licensed the drug and its unclear yet the implications for other diseases, but researchers say the results could translate into humans quickly, at least by drug development standards.

I do think its very rapidly translatable, Watts said. Based on the data theyre showing here, and based on the unmet need, this appears to be something that could be translated pretty quickly into a Phase I trial.

The rest is here:
Ionis, leading MS researcher throw antisense at a new type of brain cells - Endpoints News

The government unveiled its plans to invest 2.8 trillion won ($2.3 billion) in developing new key technologies to foster the bio-health industry over the next decade.

The Ministries of Health and Welfare, Science and ICT, and Trade, Industry and Energy said on Friday that two interagency projects -- new drug development and regenerative medicine technology development -- had passed the preliminary feasibility study last month.

The two national projects are part of the Bio-Health Industry Innovation Strategy announced by the government in May last year.

In pursuing new drug development as a state project, the government will provide step-by-step support, starting from basic research, going through nonclinical and clinical trials, and reaching test manufacture and mass production.

According to the viability study, the project will likely create 2.1 trillion won in industrial production for 10 years from 2021, to emerge as the largest R&D project to be conducted by the Ministry of Health and Welfare.

The three ministries said they plan to support the project by abolishing barriers as if they were one ministry. To this end, they have established a unified administrative system for the project by building up their capabilities, providing integrated consultation and support customized to the needs of universities, research institutions, and businesses.

Through the project, the government aims to develop blockbuster new drugs, each with annual sales of more than 1 trillion won ($830 million) over the next decade while enhancing the pharmaceutical industry's competitiveness.

Concerning the development of regenerative medicine technology, the government will provide support throughout the period, from the core basics and the original technology to the clinical stage of therapeutic and therapeutic technologies for regenerative medicines.

The field of regenerative medicine, despite expectations as a future medical technology, has experienced limitations in developing new technologies because of the legal system.

After the National Assembly passed the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals last year, research and development conditions and ecosystems for the regenerative medicine field have made marked improvement.

Encouraged by the brighter prospect, the government has decided to invest 595.5 billion won in this area for 10 years from 2021.

It plans to focus on strengthening the technological competitiveness of stem cell therapy products and core technologies with high potential for future growth, such as gene therapy and tissue engineering materials.

"Through the development of the bio-health industry, we will develop innovative new drugs to treat rare, incurable diseases, protect health sovereignty through localization of pharmaceuticals and medical technologies, and strengthen public health," said Im In-taek, director-general of the Health Industry Policy Bureau in the health and welfare affairs ministry.

Based on the results of the recent preliminary feasibility study, the three related ministries will go all out for the project's success, Im added.

corea022@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Originally posted here:
Korea to invest 2.8 trillion in promoting bio-health sector - Korea Biomedical Review

New York, July 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Brain Tumor Therapeutics Market Research Report by Type, by Therapy - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913675/?utm_source=GNW

On the basis of Type, the Brain Tumor Therapeutics Market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.

On the basis of Therapy, the Brain Tumor Therapeutics Market is studied across Gene Therapy, Immunotherapy, and Tissue Engineering.

On the basis of Geography, the Brain Tumor Therapeutics Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Brain Tumor Therapeutics Market including GlaxoSmithKline PLC, Johnson & Johnson, AstraZeneca PLC, Bristol-Myers Squibb Co, Pfizer Inc., Amgen Inc., Bayer AG, Eisai Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., and Novartis AG.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Brain Tumor Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Brain Tumor Therapeutics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Tumor Therapeutics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Tumor Therapeutics Market?4. What is the competitive strategic window for opportunities in the Global Brain Tumor Therapeutics Market?5. What are the technology trends and regulatory frameworks in the Global Brain Tumor Therapeutics Market?6. What are the modes and strategic moves considered suitable for entering the Global Brain Tumor Therapeutics Market?Read the full report: https://www.reportlinker.com/p05913675/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
The Global Brain Tumor Therapeutics Market is expected to grow from USD 2,252.58 Million in 2019 to USD 3,420.14 Million by the end of 2025 at a...

The Ample Market Research Added A new industry research report that focuses on Cancer Gene Therapy Market and delivers in-depth market analysis and future outlook of Cancer Gene Therapy market. The study covers significant data which makes the research report a handy resource for managers, analysts, industry experts, and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges.

This is the latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions.

The report begins with a brief introduction and market overview of the Cancer Gene Therapy industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed, along with current trends and policies in the industry.

Latest Sample Copy of this Cancer Gene Therapy Market Report:https://www.amplemarketreports.com/sample-request/global-cancer-gene-therapy-market-1770310.html

The report offers an extensive analysis of key drivers, leading market players, key segments, and regions. Besides this, the experts have deeply studied different geographical areas and presented a competitive scenario to assist new entrants, leading market players, and investors to determine emerging economies. These insights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the global market.

The key players profiled in this report include: Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Altor BioScience, Amgen, Argenx, BioCancell, GlaxoSmithKline, Merck, OncoGenex Pharmaceuticals, Transgene

The key product type of Cancer Gene Therapy market are: Oncolytic Virotherapy, Gene Transfer, Gene-Induced Immunotherapy

The end users/applications listed in the report are: Hospitals, Diagnostics Centers, Research Institutes

The report provides a detailed study of the growth rate of every segment with the help of charts and tables. Furthermore, various regions related to the growth of the market are analyzed in the report.

These regions include: North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC)

Analysts have revealed that the Cancer Gene Therapy market has shown several significant developments over the past few years. The report offers sound predictions on market value and volume that can be beneficial for the market players, investors, stakeholders, and new entrants to gain detailed insights and obtain a leading position in the market.

Get Complete Report in your Inbox within 24 hours Now at : https://www.amplemarketreports.com/buy-report.html?report=1770310&format=1

The research presents the performance of each player active in the Cancer Gene Therapy market. It also offers a summary and highlights the current advancements of each player in the market. This piece of data is a great source of study material for the investors and stakeholders interested in the market. In addition, the report offers insights on suppliers, buyers, and merchants in the market. Along with this, a comprehensive analysis of consumption, market share, and growth rate of each application is offered for the historic period.

Cancer Gene Therapy market Following Details Segment by Table of Contents:

1 Cancer Gene Therapy market Overview

2 Manufacturers Profiles

3 Cancer Gene Therapy Market Competition, by Players

4 Cancer Gene Therapy Market Size by Regions

5 North America Cancer Gene Therapy Revenue by Countries

6 Europe Cancer Gene Therapy Revenue by Countries

7 Asia-Pacific Cancer Gene Therapy Revenue by Countries

8 South America Cancer Gene Therapy Revenue by Countries

9 The Middle East and Africa Cancer Gene Therapy Press by Countries

10 Cancer Gene Therapy market Segment by Type

11 Cancer Gene Therapy Market Segment by Application

12 Cancer Gene Therapy Market Size Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Request a discount on standard prices of this premium research: https://www.amplemarketreports.com/discount-request/global-cancer-gene-therapy-market-1770310.html

You can also get individual chapter wise section or region wise report versions like North America, Europe or Asia or Country like US, UK, China and other.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to deliver reports that have the perfect concoction of useful data.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

Website: http://www.amplemarketreports.com

Follow this link:
Cancer Gene Therapy Market Will Generate Massive Revenue In Future - A Comprehensive Study On Key Players Adaptimmune, Bluebird bio, Celgene, Shanghai...

The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Here is the original post:
Genetic Modification Therapies Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape,...

Data Bridge Market Research has recently added a concise research on the Prostate Cancer Therapeutics Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated. As per study key players of this market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson

Prostate cancer therapeutics marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific, Brazil, Peru, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Kuwait, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Major Market Competitors/Players:Global Prostate Cancer Therapeutics Market

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increased geriatric population will enhance the growth of the prostate cancer therapeutics market in the forecast period of 2020-2027. On the other hand, limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Increasing cost of the treatment and adverse impact of treatment along with less success rate will acts as a restraint factor for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Competitive Landscape and Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to prostate cancer therapeutics market.

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @

https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-prostate-cancer-therapeutics-market

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Kuwait, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Peru, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer therapeutics market due to increasing occurrence of prostate cancer and high mortality rate along with rising investment in research and development of advanced solutions while Asia-Pacific will witness a growth in forecast period of 2020-2027 because of increasing awareness among people regarding tumours and improvement in healthcare infrastructure in this regions.

The country section of the prostate cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Major Market Drivers and Restraints:

Reasons to Purchase this Report

Customization of the Report

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more:
COVID-19 UPDATE: Prostate Cancer Therapeutics Market Increase In Research & Development In Oncology Therapeutic Area with Study Objectives,...

Prostate Cancer Therapeutics Market report covers many business strategies such as new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to amplify their footprints in the market. According to this report, the global market is anticipated to see a relatively higher growth rate during the forecast period. The market drivers and restraints have been explained in this industry report using SWOT analysis. The market share of major competitors on global level is also studied in the Prostate Cancer Therapeutics Market report where key areas such as Europe, North America, Asia Pacific and South America are covered in this market research report.

Prostate cancer therapeutics marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific, Brazil, Peru, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Kuwait, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Major Market Competitors/Players:Global Prostate Cancer Therapeutics Market

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increased geriatric population will enhance the growth of the prostate cancer therapeutics market in the forecast period of 2020-2027. On the other hand, limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Increasing cost of the treatment and adverse impact of treatment along with less success rate will acts as a restraint factor for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Competitive Landscape and Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to prostate cancer therapeutics market.

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-prostate-cancer-therapeutics-market

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Kuwait, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Peru, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer therapeutics market due to increasing occurrence of prostate cancer and high mortality rate along with rising investment in research and development of advanced solutions while Asia-Pacific will witness a growth in forecast period of 2020-2027 because of increasing awareness among people regarding tumours and improvement in healthcare infrastructure in this regions.

The country section of the prostate cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Major Market Drivers and Restraints:

Reasons to Purchase this Report

Customization of the Report

Read More @ https://www.databridgemarketresearch.com/reports/global-prostate-cancer-therapeutics-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Prostate Cancer Therapeutics Market with Rising Demand & Huge Application Potential from Industry by 2026 - 3rd Watch News

Global Prostate Cancer Therapeutics Market report covers many business strategies such as new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to amplify their footprints in the market. According to this report, the global market is anticipated to see a relatively higher growth rate during the forecast period. The market drivers and restraints have been explained in this industry report using SWOT analysis. The market share of major competitors on global level is also studied in the Global Prostate Cancer Therapeutics Market report where key areas such as Europe, North America, Asia Pacific and South America are covered in this market research report.

The market research data included in this Global Prostate Cancer Therapeutics Market report is analysed and forecasted using market statistical and coherent models. The key research methodology utilized here by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. This global market report additionally encompasses predictions utilizing a practical arrangement of suspicions and techniques. A lot of hard work has been put together and no stone is left unturned while generating this market research report. Global Prostate Cancer Therapeutics Market is a proficient and comprehensive report that focuses on primary and secondary market drivers, market share, leading segments and geographical analysis.

Global Prostate Cancer Therapeutics Market is expected to growing at a CAGR of 12.5% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Download Free PDF Sample Copy of[emailprotected]https://databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market,By Drug Type (Hormonal Therapy, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist, Anti-Androgens, Immunotherapy, Targeted Therapy, Chemotherapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Major Market Competitors/Players:

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Major Market Drivers and Restraints:

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Competitive Analysis:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of prostate cancer therapeutics market for global, Europe, North America, Asia Pacific and South America.

Reasons to Purchase this Report

Order a Copy of This ResearchReport @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-prostate-cancer-therapeutics-market

Customization of the Report

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read this article:
Global Prostate Cancer Therapeutics Market Future Demand (COVID 19 Impact Analysis) & Growth Analysis with Forecast up to 2027 - 3rd Watch News

Data Bridge Market Research has recently added a concise research on the Clinical Laboratory Services Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated.

Clinical laboratory services marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2020 to 2027 and expected to reach USD 217,941.33 million by 2027 from USD 134,692.52 million in 2019. Rising demand for early and accurate disease diagnosis is the factors for the market growth.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-clinical-laboratory-services-market&captain

Clinical laboratory services is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

The major players covered in the report are:-

Mayo Foundation for Medical Education and Research (MFMER), Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Spectra Laboratories (A Subsidiary of Fresenius Medical Care AG & Co. KGaA), DaVita Inc., Eurofins Scientific, UNILABS, SYNLAB International GmbH, MIRACA HOLDINGS Inc., Sonic Healthcare, ACM Global Laboratories, amedes Group, LifeLabs, Alere (A Subsidiary of Abbott), Charles River, Siemens Healthineers AG, BioReference Laboratories, Inc., NeoGenomics Laboratories, Inc., KingMed Diagnostics, Genomic Health, among other players domestic and global. Clinical laboratory services market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many business expansion and developments are also initiated by the companies worldwide which are also accelerating the growth of global clinical laboratory services market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for Clinical Laboratory Services through expanded model range.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Global Clinical Laboratory Services Market By Specialty (Clinical Chemistry Testing, Hematology Testing, Microbiology Testing, Immunology Testing, Drugs of Abuse Testing, Cytology Testing, Genetic Testing), Provider (Hospital-Based Laboratories, Independent & Reference Laboratories, Nursing and Physician Office-Based Laboratories), Application (Bioanalytical & Lab Chemistry Services, Drug Development Related Services, Drug Discovery Related Services, Toxicology Testing Services, Cell & Gene Therapy Related Services, Preclinical & Clinical Trial Related Services, Other Clinical Laboratory Services), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Market Trends and Forecast to 2027

Rising demand of clinical laboratory services across the world is one of the prominent factors for increasing demand of clinical chemistry testing. For instance, yearly in the U.K., the usually citizen has 14 tests completed by a laboratory specialist. However in the U.S., laboratory testing is the only highest-volume medical activity and approximately 13,000 million tests are performed per year. Hence, this factor has led the patients to shift towards clinical chemistry testing because it offers a wide range of tests which are performed in the clinical laboratory testing. In the current scenario the technological advancements boost the patients reach to laboratory testing, which is becoming gradually more precise and affordable. For instance, point-of-care testing (POCT) is regularly applied in hospitals and other healthcare practices, so the patients not need to travel to the clinical laboratories for testing. The increasing use of point-of-care testing has reduced demand tests which are conventionally executed at industry laboratories.

Rising demand of early and accurate disease diagnosis across the globe is one of the prominent factors for an upsurge demand of clinical laboratory services. For instance, in 2018, World Health Organization projected that projected that an estimated 1.8 million new cases and almost 861,000 deaths occur due to colorectal cancer (CRC). This factor has increased the number of clinical laboratories around the globe as Delays in accessing cancer care are very common in the late-stage presentation, especially in lower vulnerable populations and resource settings.

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-clinical-laboratory-services-market&captain

Table of Contents-Snapshot Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

Country Level Analysis, By Provider

North America dominates the clinical laboratory services market as the U.S. is leader in clinical laboratory services. In North America due to better advancement in products and services, this region is dominating the clinical laboratory services. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for disease diagnosis in clinics, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and clinical diagnostic laboratories in China and India upsurge demand of clinical laboratory services. The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Read More @ https://www.databridgemarketresearch.com/reports/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Huge Investment by laboratory for Clinical Laboratory Services and New Technology Penetration

Global clinical laboratory services market also provides you with detailed market analysis for every country growth in life science industry with clinical laboratory services demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the clinical laboratory services market. The data is available for historic period 2010 to 2018.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Clinical Laboratory Services Market Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2026 - 3rd Watch News

The Global Biopreservation market report presents market dynamics focusing on all the important factors market movements depend on. It includes current market trends with a record from historic year and prediction of the forecast period. This report is a comprehensive market analysis of the Biopreservation market done on a basis of regional and global level. Important market analysis aspects covered in this report are market trends, revenue growth patterns market shares and demand and supply along with business distribution

Request For Sample Biopreservation Market[emailprotected]https://www.adroitmarketresearch.com/contacts/request-sample/645

Bio-banking is further divided into veterinary IVF, human sperm and human eggs whereas regenerative medicine is sub-divided into gene therapy, cell therapy and more. On the basis of product outlook, market is divided into laboratory information management system, media and equipment.

Biopreservation is the increase in the shelf life and developed safety of foods, using the controlled or natural antimicrobial or microbiota compounds. It is the ecological and harmful method to deal with food preservation problem and is getting the attention in the current years. Growth in the demand for the developed methods of preservation and is continuously increasing the spending on healthcare is expected to boost the biopreservation market.

Pharmaceutical companies, biotechnology firms and hospitals are gradually accepting the systems for the in-house storage of the samples and is projected to offer a substantial growth to the global biopreservation market. Increasing the investments in the R&D activities by the research communities and companies are motivated to develop the capabilities of the product is increasing the biopreservation market with large potential.

Make an enquire Before Buying This Report @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/645

Developments in the technology like virtual bio-banks are expected to experience a substantial increase in the application, results in the biopreservation market growth. Moreover, rise in the preference of maintaining the repositories of biological specimen in the regenerative medicine and organ transplantation has promoted the biopreservation industry. With the help of initiatives by government like International Society of Biological and Environmental Repositories to augment the standards of preservation, practices and bio-banking is increasing the possibility for the growth of biopreservation market during the forecast period.

Rise in the expenditure for healthcare is expected to develop the healthcare quality and developed products involve the facilities of biopreservation, by widening the growth of biopreservation market. Moreover, gene banks, bio-banks and hospitals are the substantial consumers for biopreservation industry are influencing the manufacturers to produce the technologically developed products of biopreservation to increase the outcomes of patient and enhance the biopreservation market in the coming future.

With the help of several initiatives by government in healthcare are providing the grants, contracts and funds for research results in offering the growth to R&D activities set by several companies. This results in increasing the opportunity for implementing the developed services of bio-preservation, is projected to boost the growth of biopreservation market over the forecast period. Growth in the investments of R&D by research communities and companies to expand their effective products, services and capabilities is anticipated to increase the growth of biopreservation market. For example, formation of Cooperative Human Tissue Network are addressing the measurement of bio-banking, illustrates the continuous efforts by the community of research.

Get More Information About This Report With[emailprotected]https://www.adroitmarketresearch.com/industry-reports/biopreservation-market

Geographically, regions involved in the development of biopreservation market size are Europe, North America, Latin America, Asia Pacific and Middle East & Africa. U.S biopreservation market is dominating the North America and is propelled to increase the biopreservation industry in the coming years. Asia Pacific is estimated to hold the largest biopreservation market share over the forecast period.

Key players involved in the global biopreservation market are LabVantage Solutions, Thermo-Fischer Scientific, Custom Biogenic Systems, Biomatrica, Qiagen and more.

Key Segments in the Global Biopreservation Market are-

By Cell Provider Outlook, market is segmented into:

By Application, market is segmented into:

By Product Outlook, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Biopreservation Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

See original here:
Biopreservation Market Analysis 2019-2025 Emerging Trends, Growth Drivers, Challengers, Services, Competitive Landscape and Regional Outlook &...

According to the latest report by IMARC Group, titled North America Hormone Replacement (HRT) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025, the hormone replacement market in North America reached a value of US$ 502.6 Million in 2019. Hormone replacement therapy (HRT) is the most effective treatment that is used to supplement the hormones present in low levels in the human body. This treatment is usually suggested for patients who are experiencing growth hormone deficiency, women nearing menopause and elderly who are suffering from hypogonadism.

Request Free Sample Report: https://www.imarcgroup.com/north-america-hormone-replacement-therapy-market/requestsample

HRT is considered to be useful in treating the symptoms of menopause like night sweats, hot flashes, vaginal dryness and sexual function. It also aids in minimizing the risk of cardiovascular diseases, colorectal cancer, vasomotor symptoms and osteoporosis. Apart from this, countries in the North America region support the medical transition. For instance, the Canadian Bar Association favors this process of altering primary or secondary sex characteristics through hormone therapy or a variety of surgical procedures, which in turn is boosting its demand across the region. Moreover, technological advancements, coupled with the increasing investments in research and development (R&D) activities to enhance the quality and efficiency of hormone replacement therapies, are further providing a thrust to the market growth. Looking forward, IMARC Group, expects the market to reach levels worth US$ 5.0 million by 2025 exhibiting a CAGR of 5.2% during 2020-2025.

Market Breakup by End-User:

Market Breakup by Regions:

Ask Analyst and Download Full Report with List of Figure: https://bit.ly/3ioPCze

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc.. Click request free sample report. We deliver report with-in 24 hours.

Source: steemit

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group30 N Gould St Ste RSheridan, WY 82801, USAEmail: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

See the article here:
North America Hormone Replacement Therapy Market: Demand, Share, Size, Industry Trends, Analysis and Forecast during 2020-2025 - Jewish Life News

According to the latest report by IMARC Group, titled North America Hormone Replacement (HRT) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025, the hormone replacement market in North America reached a value of US$ 502.6 Million in 2019. Hormone replacement therapy (HRT) is the most effective treatment that is used to supplement the hormones present in low levels in the human body. This treatment is usually suggested for patients who are experiencing growth hormone deficiency, women nearing menopause and elderly who are suffering from hypogonadism.

Request Free Sample Report: https://www.imarcgroup.com/north-america-hormone-replacement-therapy-market/requestsample

HRT is considered to be useful in treating the symptoms of menopause like night sweats, hot flashes, vaginal dryness and sexual function. It also aids in minimizing the risk of cardiovascular diseases, colorectal cancer, vasomotor symptoms and osteoporosis. Apart from this, countries in the North America region support the medical transition. For instance, the Canadian Bar Association favors this process of altering primary or secondary sex characteristics through hormone therapy or a variety of surgical procedures, which in turn is boosting its demand across the region. Moreover, technological advancements, coupled with the increasing investments in research and development (R&D) activities to enhance the quality and efficiency of hormone replacement therapies, are further providing a thrust to the market growth. Looking forward, IMARC Group, expects the market to reach levels worth US$ 5.0 million by 2025 exhibiting a CAGR of 5.2% during 2020-2025.

Market Breakup by End-User:

Market Breakup by Regions:

Ask Analyst and Download Full Report with List of Figure: https://bit.ly/3ioPCze

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc.. Click request free sample report. We deliver report with-in 24 hours.

Source: steemit

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group30 N Gould St Ste RSheridan, WY 82801, USAEmail: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

View original post here:
North America Hormone Replacement Therapy Market: Share, Industry Trends, Price, Size, Demand and Forecast to 2020-2025 - 3rd Watch News

For the first time in the Smithsonian Conservation Biology Institutes (SCBI) history, ungulate keepers celebrated the birth of a male Hartmanns mountain zebra at the Front Royal, Virginia, facility. The colt was born overnight July 2 to 6-year-old mother Mackenzie and 5-year-old father Rogan. He is the first offspring for both parents. Ungulate keepers are closely monitoring the colt, and they report that he appears to be nursing well and sticking close by Mackenzies side.

Before their arrival at SCBI, Mackenzie and Rogan received a recommendation to breed from the Association of Zoos and Aquariums Species Survival Plan (SSP). The SSP scientists determine which animals to breed by considering their genetic makeup, health, personality and temperament, among other factors. In October 2018, Mackenzie and Rogan were transferred to SCBI from the Elmwood Park Zoo in Pennsylvania and the Cleveland Zoo in Ohio, respectively. Females typically reach sexual maturity around 2 to 3 years of age, while males become sexually mature around age 4 or 5. The pair bred naturally in June and July of 2019; Hartmanns mountain zebra gestation is about one year.

Each zebra is a unique individual, and keepers are looking forward to seeing how the colts personality develops. While mother Mackenzie is feisty and a bit standoffish, father Rogan is quirky and easygoing. The colt lives with Mackenzie and an unrelated female, 7-year-old Xolani, in a herd. Since male zebras do not provide any parental care to their offspring, Rogan lives in a separate enclosure nearby. Although the colt sticks close by Mackenzies side now, keepers say they are excited to see the foal explore his surrounding and watch his curiosity grow. Over the next two months, the colt will start sampling grass and pellets.

As a public health precaution due to COVID-19, the Smithsonians National Zoo and Conservation Biology Institute is temporarily closed to the public.Animal keepers and veterinary staff remain working on site at the Zoo and SCBI to provide the usual highest quality care for the animals.Additional information on the Zoos COVID-19 response is posted to theZoos website. The Zoo will share updates on the colt on Facebook, Instagram and Twitter.

Hartmanns mountain zebras are a subspecies of the mountain zebra, which is one of three zebra species. Considered vulnerable by the International Union for Conservation of Nature, Hartmanns mountain zebras live in dry mountain habitats of Namibia. Unlike other zebra species, Hartmann's mountain zebras live in small herds, have vertical stripes on their neck and torso and horizontal stripes on their backside, and have a small fold of skin under their chin (called a dewlap). With less than 25,000 individuals left in the wild, the biggest threat to this species survival is habitat loss and fragmentation as the result of livestock production and agriculture.

The Smithsonians National Zoos legacy of conservation work extends beyond the public Zoo in Washington, D.C., to SCBI in Front Royal, Virginia. Scientists at SCBI study and breed more than 20 species, including some that were once extinct in the wild, such as black-footed ferrets and scimitar-horned oryx. Animals thrive in specialized barns and building complexes spread over more than 3,200 acres. The sprawling environment allows for unique studies that contribute to the survival of threatened, difficult-to-breed species with distinct needs, especially those requiring large areas, natural group sizes and minimal public disturbance.

SCBI spearheads research programs at its headquarters in Virginia, the Zoo in Washington, D.C., and at field research stations and training sites worldwide. SCBI scientists tackle some of todays most complex conservation challenges by applying and sharing what they learn about animal behavior and reproduction, ecology, genetics, migration and conservation sustainability.

# # #

Read the rest here:
Hartmann's Mountain Zebra Born at the Smithsonian Conservation Biology Institute - Smithsonian's National Zoo and Conservation Biology Institute

Animal models, especially mice, have given scientists valuable insights into the mechanisms behind countless human diseases. They have been instrumental to the discovery of drug targets, metabolic pathways, and gene function. Theyve helped to lay bare the basic biochemistry of metabolism, hunger, cognition, and aging. Because mice are, to a certain extent, miniature facsimiles of human anatomy and genetics, science has an array of tools at its disposal to manipulate and visualize their bodily processes in real time, in highly controlled settings.

But, as the recent Covid-19 pandemic has revealed, science doesnt always have the tools to minimize loss of animal life. As the pandemic took hold and academic research labs across the U.S. shuttered indefinitely, scientists were faced with an unprecedented animal care dilemma. Without the teams of veterinary nurses and technicians who usually attend to the animals daily, many labs were forced to resort to wholesale euthanasia. Some labs sacrificed hundreds of animals, and were criticized harshly for their management of their experimental colonies. Many started to consider more durable, long-term plans for preserving and storing their mouse lines.

In the lab where I work at the University of California, San Francisco, and where for the past two years Ive been the designated rodent surgeon, we were asked to euthanize all but our most irreplaceable mice. As new animal researchers, we are trained to sacrifice our mice humanely to give them a dignified death. Returning to lab after the shutdown to find rows of empty racks that once held cages of mice we had worked with for months was a shock, and it was hard to conjure dignity in that moment.

That experience led me to reflect on how we as a research community use animal models in biomedical research, and how we might better use them in the future. And Ive become increasingly convinced that the animal model of the future will live not in a cage but in a computer chip: By simulating biological systems rather than experimenting with them, we can make drug development and biomedical research safer, more efficient, and more effective.

This is not to say that researchers treatment of animals has been haphazard. Research in animal models is highly regulated. These regulations vary in austerity from country to country and institution to institution, but they revolve around a common set of principles known as the three Rs: Replace the use of animals when possible, reduce the number of animals used per experiment, and refine methods to minimize suffering and improve welfare.

As the recent Covid-19 pandemic has revealed, science doesnt always have the tools to minimize loss of animal life.

A few years ago, when I was a new mouse surgeon, the three Rs were the guiding tenets of a week-long course I took at the Ren Remie Surgical Skills Center in Almere, Netherlands. The centers founder, Ren Remie, advocated for meticulous surgical technique, held to the same standards of sterility and post-operative care as any human surgical procedure. But he was also a proponent of the thinking that longer-term strategies can hasten recovery time from infection and surgical procedures. For instance, Remie and other researchers advocate whats called environmental enrichment, a method that helps animals cope with the inherent stress of being isolated after a surgical procedure or during an experiment. The researchers place toys, nesting material, or other inanimate objects in the cage that allow the mouse to engage with its surroundings, similar to the way it would in the wild. Studies suggest that environmental enrichment may even promote wound healing in rats.

But the success of strategies like environmental enrichment highlights an inherent weakness of the animal research model: An animals behavior is often extremely sensitive to its environment, in ways that are difficult if not impossible to control. This raises a perennial issue in biomedical research of just how reliably conclusions drawn based on studies in mice can be faithfully applied to human disease treatment. For instance, rodents are housed in groups as a rule, but certain kinds of experiments and treatments require them to be isolated, triggering a stress response that could significantly affect their immune activation. Studies have shown that mice and rats who live with companions fare better against injury, stroke, and even tumor growth than their lonely counterparts. As a result, when mice studies ask questions about human diseases, the housing status of the mouse is often a confounding factor. Even slight variation in the ambient temperature of a mouses housing room can cause stress responses that affect experimental outcomes. This variability is one reason that treatments that seem promising in mice often produce underwhelming outcomes in human clinical trials.

One attractive complement to animal studies that may address some of these shortcomings is in silico, or on a chip medicine. In silico models apply computational modeling strategies to genomic data to predict physiological responses to drugs or other stimuli. Although they are far from being able to replicate the full complexity of a living, sentient being, the U.S. Food and Drug Administration has begun consider computer modeling-based strategies to update the cumbersome and costly clinical trial pipeline. Research with in vitro models, which attempt to replicate animal physiology in test-tube style experiments, have also shown promise. These efforts have given birth to projects like the Comprehensive in Vitro Proarrhythmia Assay initiative, which integrates modeling and in vitro strategies to evaluate the potential for new drugs to cause heart rate abnormalities

Likewise, in 2013, the European Commission assembled a consortium of research groups known as the Avicenna Alliance to unify academia and industry around a set of standards for computer modeling in medicine. Based in Belgium but comprised of independent organizations around the world, the goal of the Alliance is to enable virtual clinical trials whose results can be validated by the same kinds of rigorous standards that are applied to traditional clinical trials.

As the Avicenna Alliance envisions them, virtual clinical trials would be based on unique genetic models derived from individual patients, rather than on large, genetically variable sample groups. Conceivably, this could allow a researcher to simulate a patients unique response to a treatment strategy, capturing the effects of subtle variations in baseline metabolism, bodyweight, or underlying health conditions that might influence the patients treatment outcomes. It might also significantly reduce the time and expense traditionally required to usher a new drug or medical device from the lab bench to the clinic potentially lowering the barrier to care for large swaths of the population who cant afford the often-astronomical costs of life-saving medications.

In silico clinical trials, if and when they are realized, could also address the long-standing problem of sample bias in drug development. Demographically, clinical trials tend to be disproportionately White and, until recently, overwhelmingly male. They therefore dont fully capture the therapeutic value and potential risks that drugs present to the patients who eventually rely on them. If in silico strategies become widely adopted, theyll hold potential to both increase the efficacy of new drugs and expand access to treatment.

The ethical debate around the use of animals in research has roiled for hundreds of years and will likely continue to do so. But what the Covid-19 outbreak has made clear is that there are severe weaknesses in the current animal model paradigm. As experiments have come to a halt during the coronavirus lockdowns, researchers have been given time to consider new, more sustainable approaches to discovery. Hopefully, we will look beyond the short-term technical challenges that will inevitably accompany the resumption of business as usual and gaze further afield, toward more humane, more modernized approaches to doing science.

Lindsay Gray is a lab manager at the University of California, San Francisco.

View post:
In the Future, Lab Mice Will Live in Computer Chips, Not Cages - Undark Magazine

We hold these truths to be self-evident, that all men are created equal, that they are endowed by their Creator with certain unalienable Rights, that among these are Life, Liberty, and the pursuit of Happiness.

Nothing fills me with a greater awe and sense of purpose than this ideal. It is the essence of my lifes work in teaching peace and justice. As an educator I believe that all of humanity is improved in recognizing equality in basic human rights and delivering on promises of equal opportunity. Unfortunately, however, this purpose doesnt generally register as patriotism; my country has failed to take equality seriously. Instead we promote mythology, an ongoing white liethe farcewhich asserts an America created as a model for humankind by wise and justice-minded Founding Fathers.

Early challenges to that myth by eloquent victims of the American reality include one from July 5, 1852, when former slave Frederick Douglass addressed the nation with his question, "What to the Slave is the Fourth of July?" at an Independence Day celebration:

Fellow-citizens! I will not enlarge further on your national inconsistencies. The existence of slavery in this country brands your republicanism as a sham, your humanity as a base pretense, and your Christianity as a lie.

Can we imagine that in 2020 minorities and persons of color are still asking for access to the American Dream, but also for permission to live? The nightmare of injustice is structural, systematic, intentional, and persistent, but were tolddecade after decadethat it is necessary to be patient and it is only a few bad apples.

We never acknowledge that the bad apples, just like the injustice, are produced in every city on every day.

The descendants of slaves carry the genetics raped into their family trees. Our streets are filled with signs honoring the rapists names. The farce says these ignoble criminals should be celebrated.

We do not teach that George Washingtons dentures were made from human teeth or ivory, tell the white lie that they are made out of wood instead of admitting there is a good chance they were purchased at cut-rate prices from slaves or, in the very best case, from desperately poor people.

We do not teach that while Benjamin Franklin eventually saw the moral need to abolish slavery, the equality pronounced in declaring independence did not extend to the slaves he owned until 1781. The White House was built with slave labor. Thomas Jefferson fathered children with Sally Hemings. How does a 16-year-old slave end up pregnant by her owner?

This social malady is present in the jokes about nooses and the insistence of those who tell them. Forget that there have been thousands of lynchings and that the racialized terror continues to traumatize communities of color. This buffoonery insists that it is not racist to joke, even when the jokes are about hate crimes. Some are inspired to mock the murder of George Floyd, posting photos of themselves kneeling on each other's necks to mimic the murder of George Floyd, or to make jokes about not being able to breathe

The problems are not isolated. Messages of animus come from everywhere, the White House with its ongoing bigotry has no problem making clear that people of color should go back to where they came from regardless of whether or not they were born in the US. Police departments have used violent militaristic responses to peaceful Black Lives Matter gatherings, with some officers declaring they are ready for a civil war; We are just going to go out and start slaughtering them f------ n------.

Sanctioning the history of the United States of America is always challenging. Sanction, contranym (a word with two different and contradictory meanings), is understood as both a threatened penalty and also as approval. Elaborate displays of patriotism tend toward the later, when progress demands the former. I am calling for negative sanctions on teaching American history from the point of view of white male propertied slaveowners. I would positively sanction teaching American history by equally honoring all the voices from all groups.

A gritty reality: A bunch of wealthy white slave owning capitalists got tired of paying taxes. They wrote a Constitution and created an Electoral College to protect the slave trade. It is time that we started telling the truth about the past and were honest about the present. A racist bully lost the popular vote by 3 million votes but occupies the office of the President because of an institution designed to perpetuate inequality. We no longer have signs that say colored but we see the same outcomes in everything from life expectancy and the lethality of the coronavirus to wealth and incarcerations disparities. We have never atoned or made reparations for this past, it is time to take equality seriously.

Wim Laven, Ph.D., syndicated by PeaceVoice, teaches courses in political science and conflict resolution.

Continue reading here:
The Farce of July | Columnists - Anchorage Press

A 3,960-g female infant is born at 37 weeks of gestation to a 25-year-old gravida 2, para 1-0-0-1 woman via vaginal delivery. The pregnancy had been complicated by a history of depression not requiring pharmacologic treatment, a urinary tract infection treated successfully, fetal abdominal distention and ascites, and polyhydramnios requiring 3 procedures for amniotic fluid reduction. Noninvasive prenatal testing and -fetoprotein levels were normal.

Apgar scores are 6 and 8 at 1 and 5 minutes, respectively. The infant has decreased respiratory effort but improves with continuous positive airway pressure and is weaned to room air while in the delivery room with no further respiratory concerns. Because of the significant abdominal distention, the patient is transferred to the NICU where the physical examination findings are significant for abdominal distention, an abdominal circumference of 38 cm, palpable bowel loops, and absent bowel sounds. Other significant findings include bilateral webbing of the second and third toes and bilateral fusion of

Read more from the original source:
Case 2: Term Female Newborn with Prenatal Diagnosis of Abdominal Distention and Ascites - AAP News

The coronavirus pandemic is a daily reminder of the far-reachingconsequences of apathogens successful invasion of human cells. And, as a new University of Toronto study on bacterial toxins shows, it does not take much for these encounters to turn deadly.

The research found that two almost identical bacterial toxins cause distinct illnesses diarrhea and fatal toxic shock syndrome by binding unrelated human receptors. It also highlights a mechanism by which pathogens have evolved distinct receptor preferences to infect different organs.

I always think of bacterial toxins as fascinating machines of death in how they find new ways to enter host tissue, saysMikko Taipale, an assistant professor of molecular genetics at the Donnelly Centre for Cellular and Biomolecular Research.

Taipaleco-led the study,published recently in the journalCell, withRoman MelnykandJean-Philippe Julien, both senior scientists at the Hospital for Sick Children and faculty members in U of Ts department of biochemistry.

Many are familiar withClostridium difficile, a gut-dwelling bacterium that can cause diarrhea. Lesser known is its close relative,Paeniclostridium sordellii, which also lives in the gut and in the female reproductive tract. Infections are rare but fatal and can occur when the bacterial toxin escapes into the bloodstream, during birth for example, and spreads into the lungs and other organs.

Both species are thought to be part of the microbiome, the bodys resident bacteria, but its not clear why they harm some people and not others.

The toxin released byC. difficileacts through Frizzled receptor proteins, which play a role in tissue regeneration. Yet, whileP. sordelliiproduces a similar toxin, it does not bind in the same way so the researchers set out to investigate.

They took an unbiased approach by systematically switching off every gene in human cells and exposing them to theP. sordelliitoxin. Cells that survived turned out to lack genes encoding cell surface proteins called semaphorins, and other experiments confirmed that two members of this class, Semaphorin6A and Semaphorin6B, are indeed the receptors for the toxin. Both receptors are present in the lungs, as expected, though their role there remains unclear.

Knowing the receptor opens the door to finding treatment. The researchers were able to halt infection in mice by co-injecting the toxin with purified semaphorin fragments, which bound and neutralized the toxin before it could reach the real receptors.

But the finding led to more surprises.

Like Frizzled, semaphorins play important roles in the body most notably in developing the nervous system, where they help guide projecting nerve fibers. Even more surprising was that it binds a receptor with no structural resemblance to Frizzled.

Here we have two toxins that are so similar to each other, but they use completely different receptors, says Taipale. We did not expect to find that.

The reason is a tiny differencebetween C. difficileandP. sordellii in particular, the surface though which both toxins contact their receptors, as revealed by cryo electron microscopy. Each toxin protein is composed of about 2,500 amino-acids and the researchers were able to pinpoint those that directly engage with the receptor. Swapping a mere 15 of these amino acids between the two toxins was sufficient to switch receptor preference. In other words, they created a P. sordellii toxin that targeted Frizzled and vice versa.

We were floored when we saw that the toxins shared a surface that each evolved to uniquely interact with distinct cells, says Julien.

It appears that, while the rest of the toxin is under strong evolutionary pressure to remain unchanged, the receptor-binding surface is free from such constraints. This allows toxins to evolve into variants that bind new receptors to invade other tissues and hosts.

Receptor switching is not unique to bacteria, however. SARS-CoV-2 and coronavirus strains that cause common cold use the same part of the now famous spike protein to bind to diverse receptors, which might explain differences in disease severity.

This is a nice example of how viruses and bacteria from completely different domains of life have found similar molecular tactics to change their receptor targets in human cells, says Taipale.

It also reminds us how much cool biology one can find in the microbial world.

The research was supported by the CIFAR Azrieli Global Scholar program, the Ontario Early Researcher Awards programand the Canada Research Chairs program.

More:
Study by U of T researchers reveals how bacterial toxins evolve to cause new illnesses - News@UofT

Stem cells have been holding great promise for regenerative medicine for years. In the last decade, several studies have shown that this type of cell, which in Spanish is called mother cell because of its ability to give rise to a variety of different cell types, can be applied in regenerative medicine for diseases such as muscular and nervous system disorders, among others. Researchers and stem cell pioneers Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea. However, one of the main limitations in the application of these cell therapies is the quality of the stem cells that can be generated in the laboratory, which impedes their use for therapeutic purposes.Now, a team from the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), led by researcher Marcos Malumbres, has developed a new, simple and fast technology that enhances in vitro and in vivo the potential of stem cells to differentiate into adult cells. The research results are published in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have. The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types, says Mara Salazar-Roa, researcher at the CNIO, first author of the article and co-corresponding author.

In this study, the researchers identified an RNA sequence, called microRNA 203, which is found in the earliest embryonic stages before the embryo implants in the womb and when stem cells still have their maximum capacity to generate all the different tissues. When they added this molecule to stem cells in the laboratory, they discovered that the cells ability to convert to other cell types improved significantly.

To corroborate this, they used stem cells of human and murine origin, and of genetically modified mice. The results were spectacular, both in mouse cells and in human cells. Application of this microRNA for just 5 days boosts the potential of stem cells in all scenarios we tested and improves their ability to become other specialised cells, even months after having been in contact with the microRNA, says Salazar-Roa.

According to the study, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the door to an improved generation of different cell types necessary for the treatment of degenerative diseases.

Malumbres, head of the CNIO Cell and Cancer Division Group, says: To bring this asset to the clinic, collaboration with laboratories or companies that want to exploit this technology is now necessary in each specific case. In this context, Salazar-Roa recently participated, in close collaboration with the CNIOs Innovation team, in prestigious innovation programs such as IDEA2 Global of the Massachusetts Institute of Technology (MIT) and CaixaImpulse of the la Caixa Foundation, from which they also obtained funding to start the development of this technology.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Quick and Simple Technology Enhances the Potential of Stem Cells To Differentiate Into Adult Cells - Technology Networks

LOS ANGELES As medical experts learn about the novel coronavirus, which continues to exhibit an array of ever-evolving symptoms and long-term effects, researchers have found that the deadly illness can have deleterious impacts on the heart and brain.

A recent study published on June 25 in the journalCell Reports Medicine, found that while COVID-19 is commonly known as a respiratory illness, the disease has also been known to instigate inflammatory responses in the body which can negatively affect the function of ones heart and brain.

According to the study, researchers observed SARS-CoV-2 infecting human heart cells that were grown from stem cells in a lab. Within 72 hours of infection, the virus managed to spread and replicate, killing the heart cells.

The researchers brought up the particularly alarming possibility that if COVID-19 can infect the heart cells in a laboratory setting, it could possibly infect those specific organs, prompting the need for a cardiac-specific antiviral drug screen program.

And those concerns are not unwarranted, according to doctors and other researchers who have been observing and studying the wide range of health problems and negative outcomes that appear to come with the not-yet-fully-known territory of the novel virus.

The most common coronavirus symptoms are fever, a dry cough and shortness of breath and some people are contagious despite never experiencing symptoms. But as the virus continues to spread, less common symptoms are being reported, including loss of smell, vomiting and diarrhea, along with a variety of skin problems and harmful neurological effects.

A recentreportfromDr. Robert Stevens, M.D., the associate director of the Johns Hopkins Precision Medicine Center of Excellence for Neurocritical Care, said that coronavirus patients are continuously experiencing a wide range of disconcerting effects on the brain.

Some of the neural symptoms, according to Johns Hopkins, include:

Patients are also having peripheral nerve issues, such as Guillain-Barr syndrome, which can lead to paralysis and respiratory failure, wrote Stevens. I estimate that at least half of the patients Im seeing in the COVID-19 units have neurological symptoms.

While medical experts have continuously repeated that more is still being discovered about the virus, Stevens listed some possibilities on how COVID-19, a respiratory illness, is making its way to the brain.

The first possible way is that the virus may have the capacity to enter the brain and cause a severe and sudden infection. Cases reported in China and Japan found the viruss genetic material in spinal fluid, and a case in Florida found viral particles in brain cells, Stevens wrote.

He added that viral particles in the brain and spine may occur when the virus enters the body through a patients bloodstream or nerve endings.

The second possibility is that the bodys immune system has an overreaction to the virus, causing severe inflammatory responses that cause organ and tissue damage.

The third theory is the erratic physiological changes the disease causes in the body, which involve extremely high fever and low oxygen levels in the blood, result in harmful effects to the brain.

Stevens added that there has been an abnormal observance of blood clotting that has caused some coronavirus patients to suffer strokes. A stroke could occur if a blood clot were to block or narrow arteries leading to the brain, he said.

Another illness that has been known to impact the brain in patients with COVID-19 is currently being studied by Dr. Mady Hornig, an immunologist and professor of epidemiology at Columbia University.

Hornig said that Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an illness that has been found in patients who have recovered from coronaviruses such as SARS.

TheCenters for Disease Control and Preventioncites a 2015 report from the nations top medical advisory body, the Institute of Medicine, which says that an estimated 836,000 to 2.5 million Americans suffer from ME/CFS.

The CDC says that people with ME/CFS experience severe fatigue, sleep problems, as well as difficulty with thinking and concentrating while experiencing pain and dizziness.

Hornig said SARS-CoV-1 and MERS have been associated with longer-term difficulties, in which many people appeared to have symptoms of ME/CFS.

Hornig is currently researching the long-term effects of COVID-19, and has been confronted with an array of concerning symptoms that have persisted in patients, as well as herself.

She can personally attest to the variety of symptoms that have been reported in coronavirus patients, ever since she began to experience her own COVID-19 symptoms in April that have continued to impact her daily life for the past few months.

She has also experienced cardiac complications while dealing with the illness.

Since getting sick, Hornig said shes had to carry a pulse oximeter with her, a device which registers her pulse since she began to have tachycardia episodes when her fever began to decline. Tachycardia is a condition that can make a persons heart beat abnormally fast, reducing blood flow to the rest of the body,according to the Mayo Clinic.

Hornigs most recent episode was on June 22. Her pulse registered at 135 beats per minute, which she said occurred just from her sitting at her computer. She said a normal pulse for someone her age would be around 60-70 beats per minute.

The findings on the novel virus potential effects on the heart and brain come as the CDC continues to update itslistof coronavirus symptoms and high-risk conditions for COVID-19 complications.

Notably, the CDC also removed the specific age threshold from the older adult classification. CDC now warns that among adults, risk increases steadily as you age, and its not just those over the age of 65 who are at increased risk for severe illness, the agency wrote.

Johns Hopkins has noted that younger patients in their 30s and 40s are reportedly having strokes as a result of COVID-19.

It may have something to do with the hyperactive blood-clotting system in these patients, Stevens said. Another system that is hyper-activated in patients with COVID-19 is the endothelial system, which consists of the cells that form the barrier between blood vessels and body tissue. This system is more biologically active in younger patients, and the combination of hyperactive endothelial and blood-clotting systems puts these patients at a major risk for developing blood clots.

But Stevens cautioned that more conclusive data is needed before the medical community can say with assurance that younger people are particularly susceptible to strokes caused by the novel coronavirus.

It is also plausible that theres an increase in stroke in COVID-19 patients of all ages, Stevens said.

34.052234-118.243685

Go here to read the rest:
Its not just the lungs: COVID-19 can affect the brain and heart of those infected, researchers say - WITI FOX 6 Milwaukee

Transparency Market Research (TMR) has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~ US$ 5 Bn in 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Planning To Lay Down Future Strategy? Request Brochure Of Cell Separation Technology Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

To Obtain All-Inclusive Information On Forecast Analysis Of Cell Separation Technology Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Request For Covid19 Impact Analysis

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1925

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration (CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

View original post here:
Cell Separation Technology Market by Leading Manufacturers, Demand and Growth Overview 2019 to 2027 - Jewish Life News

IVF is expensive! Here's a break-down of all the costs associated with the fertility process, which explains why it's so pricey in the first place.

Infertility is a tough emotional and physical experience and a record number of families are using Invitro Fertilization (IVF) to have babies. A report by Pew Research Center suggests that the number of assisted reproductive technology (ART) births in the UShas gone up threefold since 1996. Moreover, one in three American adults has used or knows someone who has sought after some form of fertility treatment. That is 12.7% of women aged 15-49, as stated by the CDC. IVF is the most popular form of ART treatment which apparently, is more expensive in the United States than anywhere else.

View this post on Instagram

Have you ever wondered how embryos are created in the lab? ( ): Using Standard IVF means to place both gametes, previously treated to facilitate this process, together in a petri dish. We let nature do its part and spermatozoon will run to the oocyte in the culture media drops and, if everything goes well, one day later we will have a zygote (the single cell made by the fusion of both gametes). ( ): With this process, we take every spermatozoon one by one, after a proper process, and we physically inject it inside the oocyte emulating thus the natural process. If everything goes well, one day later we will have the zygote. This zygote with only one cell will start cleavage and will increase its cell number day by day. Thus, on the day 2 of the embryo, we expect to have, average, 2-4 cells, on the 3rd day, average, 6-12, on day 4 cells should start compacting and become a new structure called Morula and fifth day, we should have a blastocyst. Feel free to ask additional questions and check our webpage - http://www.geomedicalart.com #ivfjourney #ivf #invitro #invitrofertilization #fertility #fertilityjourney #embryo #health #georgia

A post shared by GeoMedicalART (@geomedicalart) on Jul 2, 2020 at 12:05am PDT

IVF is a fertility treatment that uses a female's eggs and a male's sperm. The process involves combining the extracted egg and retrieved sperm in a laboratory dish. The mixture forms an embryo in a process called insemination, and the fertilized is then transferred to your uterus, three to five days after fertilization.

This ART technique is applied to treat infertility patients who have male factor infertility, unexplained sterility, blocked or injured fallopian tubes, ovulation illnesses, and couples with genetic disorders.

RELATED: Paid Surrogacy Is Illegal In Canada - What Other Fertility Options Are There?

Figures from Advanced Fertility Care shows that live birth success rates in the US for each IVF round is 54.9% for patients below 35 years. The percentage decreases as a person gets older, with patients below 40 years having a success rate of 21.2% and those above 42 years achieving zero live births.

In the United States, the average cost for one IVF round is $12,000 without including the cost of medication. However, the cost varies and may be as high as $15,000 or as low as $10,000. Likewise, the cost of the medication ranges between excesses of $3,000 andas low as$1,500. Thus, on average, a patient can spend up to $20,000 for one IVF cycle, and up to $60,000 for three full IVF cycles.

The treatment is quite pricy primarily because the process involves many stages of preparation before, and after the treatment that tallies up over time. Patients pay for the IVF procedure itself, in addition to regular consultations, hormone medications, and the prospect of having to undergo more than one IVF cycle.

Many factors determine the cost of IVF, which includes the patients age, medical history, and the type of procedure. The costs from the procedure are determined by the injectables, specialist care, egg and sperm retrieval, genetic testing, insemination, storing and caring for the fertilized egg (embryo), and so on. Additionally, a patients personal choices can affect the cost as well. For instance, if a person has a low pain threshold, there will be an extra cost for getting sedated or anesthetized for egg retrieval.

On the whole, finances are a big consideration when it comes to IVF, which takes 10 t0 12 days of medication, and an additional five days to grow the embryo and placing it inside the uterus. The most expensive part of IVF is when a couple opts for a pregnancy carrier. If you add the legal and agency fees, IVF costs, and reimbursement to the pregnancy carrier, the cost can vary from a low of $50,000 to a high of $100,000.

Resorting to an IVF can look like too big a step, but there are ways you can save money on IVF.

Do A Mini-IVF.The bulk of expenses for IVF treatments go to the injectables used to stimulate the growth of an egg. This medication can be very pricy, but there is a way of doing IVF with fewer meds through Mini-IVF, short for minimal stimulation IVF. Although Mini-IVF has not caught on in America, it is a procedure that reduces IVF treatment costs by using much fewer injectables. However, this method is not recommended for everyone as it could lessen the chances of success for some. Therefore, seek guidance from a clinic that specializes in the procedure if you choose Mini-IVF treatment.

Thorough Financial Planning.How much money will you need? Get detailed information concerning every aspect of the treatment and cost. You will need to know what is factored into the total cost and what is not counted in. Then, begin saving months before, and read your insurance plan to see if you are eligible for partial coverage.

Choosing An IVF Clinic.Find the clinic that will provide the treatment you need at a price you can afford. Likewise, find a clinic that offers exceptional treatment packages with guarantees and great success rates, to avoid having to undergo more than one IVF round.

NEXT:Celebrities You Didn't Know Had Fertility Issues

Sources: webmd.com, cnyfertility.com, creatingafamily.org, medicalexpress.com.

Shawn Johnson Blames Past Drug Use & Eating Disorder For Her Miscarriage

I have been a writer since 2012, and have enjoyed the journey thus far. When I am not busy writing like there's no tomorrow, I enjoy spending time with my three daughters and watching Netflix.

Read more here:
Where Is Your Money Really Going During IVF? | BabyGaga - BabyGaga

Nanotechnology is poised to revolutionize the diagnosis and treatment of patients with type 1 diabetes.

According to the WHO, in 2016, an estimated 1.6 million deaths were directly caused by diabetes. It is a chronic disease that occurs when the body is unable to produce or process a hormone called insulin, which helps regulate blood sugar levels.

Of the three major types, type 1 diabetes has proven to be the most problematic in terms of providing patients with a timely diagnosis, as patients may be asymptomatic for long periods of time with a sudden onset of symptoms well into the diseases progression.

Currently, type 1 diabetes can be diagnosed at any age, but it is mostly found in children and adolescents. Once diagnosed, patients also have a high risk of diabetes-related complications, as well as other autoimmune diseases, such as hashimotos thyroiditis or celiac disease. Therefore, early diagnosis and treatment could prevent the progression of type 1 diabetes.

At present, the diagnosis of type 1 diabetes depends on the detection of blood glucose levels and islet autoantibodies, which are markers that appear when insulin producing islet cells clusters of hormone producing cells in the pancreas are damaged. But the function of the patients cells have likely already been severely damaged by the time they receive a diagnosis.

As more and more people suffer from type 1 diabetes of the 422 million people worldwide diagnosed with diabetes in 2016, roughly 5% were categorized as type 1 the importance of early diagnosis and the urgency of effective treatments becomes ever more important. However, recent medical methods for the early diagnosis of type 1 diabetes are still limited. So, its important to develop new methods for early diagnosis and treatment.

Nanomedicine is an emerging field and provides a promising and more effective alternative to diagnose type 1 diabetes, and stands to revolutionize treatment for patients. Experts in this field, Dr. Yuanzeng Min from the School of Chemistry and Material Science at the University of Science and Technology of China (USTC) and Dr. Jianping Weng, a clinician from the First Affiliated Hospital of USTC discuss the findings in a recent reviewpublished in WIREs Nanomedicine and Nanobiotechnology.

Magnetic resonance imaging (MRI) has in itself revolutionized imaging in medicine. It takes advantage of powerful magnets to make a detailed internal picture of the body and helps doctors diagnose otherwise unseen disease or injury. To improve this technique and make it more suitable to diagnosing patients with type 1 diabetes, scientists have explored using common biomarkers of the disease, such as inflammation, and enhancing physicians ability to detect them in MRI analysis using helper materials. In this sense, nanomaterials have been shown great promise in facilitating the accumulation of imaging substrates at the targeted site, thus improving the quality of MRI imaging and the accuracy of diagnosis.

An excellent example of this is the clinical use of the nanoparticle ferumoxtran-10 or ferumoxytol. In clinical studies, there was an observed increase in pancreatic accumulation of this imaging nanoparticle in inflamed islets of type 1 diabetes patients in comparison to a healthy control group. This method is non-invasive, and the imaging materials are readily metabolized by the body without harmful side effects. This technique has been ground-breaking in visualizing insulitis, an inflammatory lesion and an early stage marker of type 1 diabetes.

Type 1 diabetes is classified as an autoimmune disease in which insulin-producing cells are destroyed by the bodys own immune system, and is affected by a number of factors, such as genetics, environment and metabolism, among others. The downregulation of the overactive immune cells that kill the insulin-producing cells has been gathering more and more attention in the medical and research community.

Studies have shown that nanoparticles have the beneficial characteristics of high drug loading and are capable of being targeted to a specific location in the body, minimizing harmful side effects usually observed in these types of therapies. Scientists have used loaded nanoparticles to carry antigenic peptides or pMHC (peptide major histocompatibility complex) to suppress the bodys immune response so that the immune cells no longer attack cells. Research has also explored encapsulating cytokines or other synthesized molecules to modulate the immune system into the nanoparticles, which could be locally administered along with modulating immune cells, such as T cells or APCs (antigen presenting cells).

Significant progress in the development of sophisticated nanotechnologies has also been seen in the past 10 years for immunotherapy and islet transplantation in type 1 diabetes. Nanotechnology has played a significant role in islet transplantation by encapsulating healthy cells with biomaterials as most of the insulin-producing cells are destroyed by the patients own immune system. The biomaterials also protect the transplanted cells from immune exclusion. In addition to avoiding a deleterious host response, encapsulated islets must receive an adequate nutrient supply and positive extracellular cues in order to survive and functionin vivo.Thus, while using nanotechnology to encapsulate cells, it alsorequires as little interference as possible with the generation of new blood vessels in the encapsulation. This is usually achieved by improving the mechanical rigidity, charge distribution, morphology, and other related parameters of the nanomaterials.

While great strides have been made, limitations in the application of nanotechnology in diagnosis and treatment of type 1 diabetes remain. For example, some nanoparticles are not specifically target islets, their production process can be complicated, and the cost is high. However, their application in this area of medicine has only just begun, and we are beginning to see the benefits of this research in clinical trials.

With research in type 1 diabetes and the development of nanotechnology, these problems will hopefully one day be solved. We believe that in the next 10-20 years there will be high chance of this type of therapy used regularly in the clinical diagnosis and treatment oftype 1 diabetes patients.

Written by: Yuanzeng Min and Jianping Weng

Reference: Wen Pan, et al. Nanotechnologys application in Type 1 diabetes. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1645

View original post here:
Earlier diagnosis and better treatment for type 1 diabetes - Advanced Science News

Depression has been shown to be prevalent during menopause, affecting as many as 70 per cent of women transitioning into menopause, say researchers.The study, published in the journal of The North American Menopause Society (NAMS), not only confirms the high prevalence of depression but also the greatest risk factors for it in postmenopausal women, as well as any relationships with anxiety and fear of death. "The findings are consistent with existing literature and emphasize the high prevalence of depressive symptoms in midlife women, particularly those with a history of depression or anxiety and chronic health conditions," said study researcher Stephanie Faubion, NAMS medical director.With the decrease in hormone production during menopause, women are more prone to a number of psychological problems, including depression, anxiety, irritability, nervousness, sadness, restlessness, memory problems, lack of confidence and concentration, and a loss of libido.

At the same time, as women age, the fear of death becomes more pronounced.

Depression and anxiety, which are the most common psychological problems that occur during the menopause transition, likely increase that fear, the researchers said.

For the current findings, the research team picked 485 postmenopausal Turkish women aged between 35 and 78 years.

The researchers sought to determine the frequency of depressive symptoms in postmenopausal women, the variables affecting it, and the levels of anxiety and fear of death.

They then evaluated the relationship between all these variables and postmenopausal depression.

They found that depression in postmenopausal women is a common and important health problem that requires further study.

In this specific study, 41 per cent of the participants were confirmed to experience some form of depression.

bu/rs/

Read more from the original source:
Going through menopause increases risk of depression in 70% women, says study - Times of India